Trevi Therapeutics in the pre-market increased by 25.8% and is worth $1.51. During the year, the indicators drop from $3.8500 to $1.2000. In February, the price rose to $3.3900 and reached its maximum. During its last trading session, the stock fell by 4.0%. Trevi Therapeutics recently announced that it has signed a formal purchase agreement in a private placement at market price with an institutional investor focused on healthcare.
Each common stock and related order for common stock are sold together at a total price of $1.62, and each pre-funded order and related order for common stock are sold together at a total price of $1.619, representing approximately $11.8 million in gross revenue.
Each pre-funded order will have a strike price of $0.001 per share and will be executed immediately until all pre-funded orders are properly executed. Purchase orders for a total of 7,299,270 ordinary shares expire 3.5 years from the date of issue, while purchase orders for a total of 7,299,270 ordinary shares expire 7 years from the date of issue. Orders for ordinary shares with an exercise price of $1.37 per share are attached and can be executed immediately.